



NIFTY OUTLOOK REPORT

20th February 2017

Prepared by: Yogesh Subnani

NIFTY FUTURE

NIFTY FUTURE :	R1:8866	R2:8905	R3:8938
PIVOT :8833	S1:8794	S2:8761	S3:8721



NIFTY DAILY CHART

CHART INTERPRETATION

MACD and Price ROC are both positive and continue in Buy mode. RSI (70) still suggests bullish momentum. Stochastic Oscillator %K (96) is above %D, indicating a Buy. But both RSI and Stochastic Oscillator are overbought. ADX is at 36 which suggest that the Uptrend is very strong. This week, the indices tested the short term average of 22dma Nifty – 8473 close above it. the indices continue to remain above the medium term average of 55dma Nifty – 8268 but above the long term average of 200dma Nifty –8356. Thus the trend in the short term, medium term and even the long term timeframe continues to remain upwards. The support for the Nifty is 8602-8572-8535-8469 and the resistance to the up move is at 8818-8833-8923-8968 levels.

INDEX OUTLOOK

NIFTY FUTURE: With the Nifty Bank index opening at all-time high levels, the Nifty also started on an optimistic note. However, follow-up pace was missing, which led the index to end only 44 points higher. Nifty futures settled at a premium of 5 points. India VIX fell 2.2% to 13.4.

We have now revised the immediate support threshold for the index upwards to 8650 region. We believe the current breather to work out the overbought conditions will attract demand at the earmarked support zone of 8650 as it is the confluence of following: $\frac{3}{4}$ 61.8% retracement of the up move post Union Budget (8537 to 8814) is placed at 8650 region $\frac{3}{4}$ Previous weeks congestion area is placed near 8670 region $\frac{3}{4}$ Lower band of the short term rising channel encompassing current up move is also placed around 8650 region • Among oscillators, the short-term stochastic has seen a rebound after cooling off to neutral level.

STRATEGY: Buy Nifty Future above 8780 for the target of 8850 -8900 with the stop loss of 8720.

SECTORAL INDICES

Key Indices – Levels to watch out for the day					
INDEX (Spot)	RESISTANCE 2	RESISTANCE 1	LTP	SUPPORT 1	SUPPORT 2
SENSEX	28900	28730	28468.75	28300	28100
NIFTY	8950	8900	8821.70	8780	8720
NIFTYBANK	20925	20750	20551.35	20375	20200
NIFTYIT	10750	10650	10527.20	10400	10300

CORPORATE NEWS

For **Bicon**, US drug regulator USFDA has accepted Mylan's biologics licence application (BLA) for a proposed biosimilar of branded Trastuzumab for treatment of certain breast and gastric cancers. The stock closed at Rs 1105 before making a new 52 week high of Rs 1123.

Cipla, a global pharmaceutical company, announced that it has launched adult Hepatitis B vaccine in India, under a co-exclusive agreement with Serum Institute of India Private Limited (SII). The shares of the company closed at Rs 593, up 1.5%

Power equipment manufacturer Bharat Heavy Electricals (BHEL) and telecom operator Idea Cellular have been excluded from the Nifty 50 index. Replacing these two firms are housing mortgage company Indiabulls Housing Finance and oil marketing company Indian Oil Corporation. The changes will come into effect from March 31, 2017. IDFC Bank will replace Bank of India in the Nifty Bank index.

ERL RESEARCH TEAM

Member Name	Designation	E-mail ID
Mr. Tuhinanshu Jain	Research Head	Tuhinanshu.jain@equityresearchlab.co.in
Mr. Yogesh Subnani	Sr. Research Analyst	Yogesh.subnani@equityresearchlab.co.in

DISCLAIMER

The information and views in this report, our website & all the service we provide are believed to be reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have the right to choose the product/s that suits them the most. Investment in Stocks has its own risks. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. We, however, do not vouch for the accuracy or the completeness thereof. This material is for personal information and we are not responsible for any loss incurred based upon it & takes no responsibility whatsoever for any financial profit s or loss which may arise from the recommendations above. The stock price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice.

Equity Research Lab does not purport to be an invitation or an offer to buy or sell any financial instrument. Analyst or any person related to Equity Research Lab might be holding positions in the stocks recommended. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Any surfing and reading of the information is the acceptance of this disclaimer.

Our Clients (Paid or Unpaid), any third party or anyone else have no rights to forward or share our calls or SMS or Report or Any Information Provided by us to/with anyone which is received directly or indirectly by them. If found so then Serious Legal Actions can be taken. Any surfing and reading of the information is the acceptance of this disclaimer.

ALL RIGHTS RESERVED.